ACTRN12615000815561已完成1 期
A pivotal in vivo bioequivalence study comparing Eumovate cream to Clobetasone butyrate cream, using the appropriate dose duration (ED50) for Eumovate cream calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Males or females
- •In good general health
- •Aged between 18-55 years of age inclusive
- •BMI between 18 and 33 inclusive
- •Laboratory tests within normal ranges or assessed not significant by the Clinical Investigator
排除标准
- •Clinically significant hypertension or circulatory disease and any clinically significant illness during the last four weeks prior to the entry into this study.
- •Caffeine intake greater than 500 mg per day prior to this study.
- •Who have been on a special diet, especially a low salt and/or fluid diet, during the 2 weeks prior to the first study day.
- •Use of topical Dermatologic drug therapy on ventral forearms.
- •Adverse reactions to topical or systemic corticosteroids.
- •Who require shaving of the ventral forearms.
- •Use of any vasoactive medication, prescription or over the counter that could modulate blood flow.
- •Use of any prescription medication within 2 weeks preceding entry into the study
- •Any obvious difference in skin colour between arms or any scarring on the forearms.
- •Females who are pregnant or lactating
- •Significant medical condition that could in the Investigator's opinion interfere with the study, or put the subject at significant risk
- •Participation in any drug or medical device study within 30 days of entering this study
研究者
相似试验
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of methylprednisolone aceponate fatty ointment applied to the skin in healthy male and female volunteers.ACTRN12620000160932Zenith Technology Corporation Limited95
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of betamethsone ointment applied to the skin in healthy male and female volunteers.Betamethasone ointment is indicated for the topical treatment of eczema and psoriasis in children and adults.Skin - Dermatological conditionsACTRN12624000107527Zenith Technology Corporation Limited90
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of 21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone fatty ointment applied to the skin in healthy male and female volunteers.21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone fatty ointment is indicated for the short term treatment of the milder form of eczema, dermatitis and other steroid responsive skin conditionsSkin - Dermatological conditionsACTRN12623000571673Zenith Technology Corporation Limited90
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of 9-fluoro-11ß-hydroxy- 16ß-methyl-3,20-dioxopregna- 1,4-diene-17,21-diyl dipropanoate cream applied to the skin in healthy male and female volunteers.ACTRN12623001003662Zenith Technology Corporation Limited90
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of 21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone ointment applied to the skin in healthy male and female volunteers.21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone ointment is indicated for the short term (up to 7 days) treatment of the milder form of eczema, dermatitis and other steroid responsive skin conditions which do not require the use of a more active topical corticosteroidSkin - Dermatological conditionsACTRN12622001421729Zenith Technology Corporation Limited90